Business Description
Passage Bio Inc
NAICS : 325412
SIC : 2834
ISIN : US7027122099
Share Class Description:
PASG: Ordinary SharesTotal Employee Number:
24Description
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.79 | |||||
Equity-to-Asset | 0.32 | |||||
Debt-to-Equity | 0.49 | |||||
Debt-to-EBITDA | -0.15 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 34.9 | |||||
3-Year EPS without NRI Growth Rate | 36.7 | |||||
3-Year FCF Growth Rate | 39.7 | |||||
3-Year Book Growth Rate | -56.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 13.35 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 35.07 | |||||
9-Day RSI | 38.15 | |||||
14-Day RSI | 40.34 | |||||
3-1 Month Momentum % | -27.04 | |||||
6-1 Month Momentum % | -49.57 | |||||
12-1 Month Momentum % | -27.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.73 | |||||
Quick Ratio | 1.73 | |||||
Cash Ratio | 1.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.2 | |||||
Shareholder Yield % | 40.31 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -128.51 | |||||
ROA % | -55.72 | |||||
ROIC % | -120.01 | |||||
3-Year ROIIC % | -390.03 | |||||
ROC (Joel Greenblatt) % | -266.87 | |||||
ROCE % | -81.28 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.28 | |||||
Price-to-Tangible-Book | 1.26 | |||||
EV-to-EBIT | 0.33 | |||||
EV-to-EBITDA | 0.33 | |||||
EV-to-FCF | 0.41 | |||||
| Price-to-Net-Current-Asset-Value | 1.48 | |||||
| Price-to-Net-Cash | 1.72 | |||||
Earnings Yield (Greenblatt) % | 303.03 | |||||
FCF Yield % | -203.84 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PASG
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Passage Bio Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -11.85 | ||
| Beta | 2.4563 | ||
| 3-Year Sharpe Ratio | -0.02 | ||
| 3-Year Sortino Ratio | -0.04 | ||
| Volatility % | 69.02 | ||
| 14-Day RSI | 40.34 | ||
| 14-Day ATR ($) | 0.571013 | ||
| 20-Day SMA ($) | 5.34025 | ||
| 12-1 Month Momentum % | -27.46 | ||
| 52-Week Range ($) | 3.29 - 20 | ||
| Shares Outstanding (Mil) | 3.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Passage Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Passage Bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 130 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 40 days | ||
| Passage Bio / Remix Therapeutics Merger Conference Call | 2026-06-24 16:30 | 6.12 (+7.75%) | ||
| General meeting for 2026 | 2026-05-19 09:00 | 5.12 (-0.19%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 4.40 (+5.77%) | ||
| Annual report for 2025 | 2026-03-03 | 8.78 (+1.50%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-03 | 8.78 (+1.50%) | ||
| Guggenheim Second Annual Healthcare Innovation Conference | 2025-11-12 09:30 | 7.70 (+20.12%) | ||
| Third quarter earnings results for 2025 | 2025-11-10 | 6.29 (+0.56%) | ||
| Chardan\'s 9th Annual Genetic Medicines Conference | 2025-10-21 15:30 | 8.54 (+3.82%) |
Show
Entries
Passage Bio Inc Frequently Asked Questions
What is Passage Bio Inc(PASG)'s stock price today?
The current price of PASG is $4.63. The 52 week high of PASG is $20.00 and 52 week low is $3.29.
When is next earnings date of Passage Bio Inc(PASG)?
The next earnings date of Passage Bio Inc(PASG) is 2026-08-12 Est..
Does Passage Bio Inc(PASG) pay dividends? If so, how much?
Passage Bio Inc(PASG) does not pay dividend.
Guru Commentaries on NAS:PASG
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Passage Bio Inc
No articles.
Headlines
See More- 1
Jun 24, 2026
Passage Bio, Remix Therapeutics announce merger agreement
Seeking Alpha • 3:15pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers